Wissenschaftliche Artikel in Englisch

Studien zum Thema Schmerzen

Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Von Staquet , Gantt , Machin  im Clin Pharmacol Ther 1978; 23: S. 397-401

A randomized, placebocontrolled, crossover trail of cannabis cigarettes in neuropathic pain. Von Wilsey, Marcotte, Tsodikov im J Pain 2008; 9(6): S. 506-521

Smoked cannabis for chronic neuropathic pain in HIV: a randomized, crossover clinical trail. Von Ware, Wang, Shapiro im CMAJ 2010; 182(14): S. 694-701

Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Von Rintala, Fiess, Tan, Holmes, Bruel im J Phys Med Rehabil 2010; 89(19): S. 840-848

Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlles trail. Von Abrams, Jay, Shade im Neurology 2007; 68(7): S. 515-521

Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: result of a randomised controlled trail. Von Berman, Symonds, Birch im Pain 2004; 112(3): 299-306

A study of levnonantradol, a cannabinol derivative, for analgesia in post operative pain. Von Kantor, Hopper im Pain 1981 S.37

Effects of nabilone, a synthetic cannabinoid, on post operative pain. Von Beaulieu im Can J Anaesth 2006 53(8): S. 769-775

Evaluation of herbal cannabis characteristics by medical users: a randomized trail. Von Ware, Decruet, Robinson im Harm Reduct J 2006; 3(1): S. 32

Analgesic effect of delta-9-THC. Von Noyes, Brunk, Baram, Canter im J Clin Pharmacol 1975; 15: S. 139-143

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trail. Von Svendsen, Jensen, Bach im BMJ 2004; 329(7460) S. 253

Evaluation on intramuscular levonantradol and placebo in acute postoperative pain. Von Jain, Ryan, McMahon, Smith im J Clin Pharmacol 1981; 21: S. 320-326

Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. Von Narang, Gibson, Wasan im J Pain 2008; 9(3): S. 254-264

The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Von Noyes, Brunk, Baram, Canter im Clin Pharmacol Ther 1975; 18: S. 84-89

A randomized, controlled stury to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Von Osterfeld, Price, Albanese im Clin J Pain 2011; 27(8): S. 668-676

Initial experiences with medicical extracts of cannabis for chronic pain: sesults from 34, N of 1  studies. Von Notcutt, Price, Miller im Anaesthesia 2004; 59(5): S.440-452

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trail. Von Wisse, Haydn, Müller im J Neurol 2006; 253(10): S. 1337-1341

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Von Wade, Rabson, House, Makela, Aram im Clin Rehabil 2003; 17: S. 18-26

Randomised Placebo Controlled Double Blind Clinical Trail of Cannabis Based Mdicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a Major Confounding Factor. Von Selvarajah, Gandhi, Emery, Tesfaye im Diabetes Care 2010; 33(1): S. 128-130

Multicenter , Double-Blind, Randomizes, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC: CBD Extract and THC Extract in Patients With Intractable Cancer Related Pain. Von Johnson, Burnell-Nugent, Lossignol, Ganae-Motan, Potts, Fallon im J Pain Sympton Manage 2010; 39(2): S. 167-179

Nabilone for the treatment of pain in fibromyalgia. von Skrabek, Galimova, Ethans, Perry im J Pain 2008; 9(2): S. 164-173

Smoked medicinal cannabis for neuropathis pain in HIV: a randomized, crossover clinical trial. Von Ellis, Toperoff, Vaida im Neuropsychopharmacology 2009; 34(3): S. 672-680

Sativex successfully treats neuropathic pain characterised by allodynia: a randomsed, double-blind, placebo-controlled clinical trail. Von Nurmikko, Serpell, Hoggart, Toomey, Morlion, Haines im Pain 2007; 133 (1-3): S. 210-220

Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neropathic pain: randomised, crossover, double blind study. Von Frank, Serpell, Hughes, Matthews, Kapur im BMJ 2008; 336(7637): S. 199-201

Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. Von Karst, Salim, Burstein, Contrad, Hoy, Schneider im JAMA 2003; 290(13): S. 1757-1760.

Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Von Buggy, Toogood, Maric, Sharpe, Lambert, Rowbotham im Pain 2003; 106(1-2): S. 169-172

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Von Blake, Robson, Ho, Jubb, McCabe im Rheumatology (Oxford) 2006; 45(1): S. 50-52

Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: psychological correlates of the analgesic response. Von Raft, Gregg, Ghia, Harris im Clin Pharmacol Ther 1977; 21: S. 26-33

A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Von Holdcroft, Maze, Dore, Tebbs, Thompson im Anesthesiology 2006; 104(5): S. 1040-1046

(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain. Von Seeling, Kneer, Buchele im Anaesthesist 2006; 55(4): S. 391-400

The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Von Ware, Fitzcharles, Joseph, Shir im Anesth Analg 2010; 110(2): S. 604-610

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Von Rog, Nurmikko, Friede, Young im Neurology 2005; 65(6): S. 812-819

Erbrechen und Übelkeit

Comparative trail of the antiemetic effects of THC and haloperidol. Von Neidhart, Gagen, Wilson, Young im Int J Clin Pharmacol Res 1981; 21: S.38-42

Ameriloration of cancer chemothera-induced nausea and vomiting by delta-0-tetrahydrocannabinol. Von Ekert, Waters, Jurk, Mobilia, Lounghnan im Med J Aust 1979; 2: S. 657-659

Tetrahydrocannabinol (THC) plus prochlorperazine (PCZ) for refractory nausea and vomiting (N/V). Von Artim, DiBella im Proc Am Soc Clin Oncol 1983; 2: S.84

Delta-9-tetrahydrocannabbinol as an antiemetics for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Von Frytak, Moertel, O´Fallon, Rubin, Creagan, O´Connel im Ann Int Med 1070; 91: S. 825-830

A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Von Johansson, Kilkku, Groenross im Can Treat Rev 1982; 9: S. 25-33

Nabilone vs placeno in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Von Levitt im Can Treat Rev 1982; 9: S. 49-53

Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Von Chan, Correia, MacLead im Pediatrics 1987; 79: S. 946-952

Nabilone: An alternative antiemetic for cancer chemotherapy. Von Dalzell, Bartlett, Lilleyman im Arch Dis Child 1986; 61: S. 502-505

Randomizied double blind comparison of delta-9-tetrahydrocannabinol (THC) and marijuana as chemotherapy antiemetics. Von Levitt, Faiman, Hawks, Wilson im Proc Am Soc Clin Oncol 1984; 3: S. 91

Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. Von Sallan, Cronin, Zelen, Zinberg im N Engl J Med 1980; 302: S- 135-138

Antimetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Von Gralla, Tyson, Bordin, Clark, Kelsen, Kris im Can Treat Rep 1984; 68: S. 163-172

Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Von Ungerleider, Andry, Fairbanks, Goodniught, Sarna, Jamison im Cancer 1982; 50: S. 636-645

Dronabinol and prochlorperazne in combination for treatment of cancer chemotherapy-induced nausea and vomititng. Von Lane, Vogel, Ferguson, Krasnow, Saiers, Hamm im J Pain Sym Manag 1991; 6: S. 352-359

Preliminary efficacy and safety of an oromucosal standaridized cannabis extract in chemothreapy-induced nausea and vomiting. Von Duran, Pérez, Abanades im Br J Clin Pharmacol 2010; 70(5): S. 656-663

Dose vs response of tetrahydroannabinol (THC) vs prochlorperazine as chemotherapy antiemetics. Von Levitt, Wilson, Bowman, Faiman, Kemel, Krepart im Proc Am Soc Clin Oncol 1981; 22: S. 422

The antiementic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. Von Colls, Ferry, Gray, Harvey, McQueen im N Z Med J 1980; 91: S. 449-451

Efficacy of terahydrocannabinol in patients refractory to standard anti-emetic therapy. Von McCabe, Smith, Goldberg, Macdonalds, Woolley, Warren im Invest New Drugs 1988; 6: S. 243-246

Superiority of nabilone over prochlorperazine as an antiemetic in patiens receiving cancer chemotherapy. Von Herman, Einhorn, Jones im N Engl J Med 1979; 300: S. 1295-1297

Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Von Crawford, Buckman im Med Oncol Tumour Pharmacother 1986; 3: S. 39-42

A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Von Niiranen, Mattson im Am J Clin Oncol 1985; 8 : S. 336-340

A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Von Jones, Durant, Greco, Robertone im Can Treat Rev 1982; 9: S. 45-48

A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopradmide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Von Cunningham, Bradley, Forrest im Eur J Can Clin Oncol 1988; 24: S. 685-689

THC or Compazine for the cancer chemotherapy patient – the UCLA study. Part II patient drug preference. Von Ungerleider, Sarna, Fairbanks, Goodnight, Andrysiak, Jamison im Am J Clin Oncol 1985; 8: S. 142-147

Antiemetic effect of terahydrocannabinol. Compared with placebo and prochloperazine in chemotherapy-associated nauseo and emesis. Von Orr, McKernan, Bloome im Arch Int Med 1980; 302: S. 1431-1433

D9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. Von Kluin-Nelemans, Nelemans, Meuwissen, Maes im Vet Hum Toxicol 1979; 21: S. 338-340

Antiemnetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. Von Sallan, Zinberg, Frei im N Engl J Med 1975; 293: S. 795-797

Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Von Ahmedzai, Carlyle, Clader, Moran im Br J Cancer 1983; 48: S. 657-663

Effcacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Von Meiri, Jhangiani, Vredenburgh im Curr Med Res Opin 2007; 23(3): S. 553-543

Delta-9-tetrahydrocannabinol as an antiemetics in cancer patients receiving high-dose methotrexate. Von Chang, Shilling, Stillman, Goldberg, Seipp, Barofsky im Ann Int Med 1979; 91: S. 819-824

A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Von Chang, Shilling, Stillman im Cancer 1981; 47: S. 1746-1751

Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. Von Einhorn, Nagy, Furnas, Williams, im J Clin Pharmacol 1981; 21: S. 64-69

Nabilone: antiemetic crossover study in cancer chemotherapy patients. Von Nagy, Furnas, Einhorn, Bond im Proc Am Soc Can Res 1978; 19: S.30

Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Von Niederle, Schutte, Schmidt im Klin Wochenschr 1986; 64: S. 362-365

Prospective randomized double-blind trail of nabilone versus domperidone in the treatment of cytotxic-induced emesis. Von SPomeroy, Fennelly, Towers im Can Chemother Pharmacol 1986; 17: S. 285-288

Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Von Steele, Gralla, Braun, Young im Can Treat Rep 1980; 64: S. 219-224

Double-blind, randomized, crossover trail of nabilone vs. placebo in cancer chemotherapy. Von Wada, Bogdon, Gunnell, Hum, Gota, Rieth im Cancer Treatment Rev. 1982; 9: S. 39-44

Randomized comparative trail of a new anti-emetic: nabilone, in cancer patients treated with cisplantin.Von George, Pejovic, Thuaire, Kramer, Wolff im Biomed Pharmacother 1983; 37: S. 24-27

Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subject with chemotherapy-induced emesis. Von Stambaugh, McAdams, Vreeland im Int J Clin Pharmacol Res 1984; 24: S. 480-485

A randomized multicenter single blind comparison of a cannabinoid anti-emetic (levonantradol) with ychlorpromazine in patients receiving their first cytotoxic chermotherapy. Von Hutcheon, Palmer, Soukop im Eur J Can Clin Oncol 1983; 19: S. 1087-1090

Mobilität und Spastik bei Multiple Sklerose

Cannabinoids in multiple sclerosisi (CAMS) study: safety and efficacy date for 12 month follow up. Von Zerjicek, Sanders, Wright im J Neurol Neurosurg Psychiatry 2005; 76(12): S. 1664 – 1669

A randomized, double-blind, placebo-controlles, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refactory spasticity caused by multiple sclerosis. Von Novotna, Mares, Ratcliffe im Eur J Neurol 2011, S. 1122-1131

Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Von Killestein, Hoogervorst, Reif im Neurology 2002 58(9) S. 1402-1407

Do cannabisbased medicinal extracts have general of specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlles study on 160 patients. Von Wade, Makela, Robson, House, Bateman im Mult Scler 2004 10(4) S. 434-441

Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Von Centonze, More, Koch im Neurol Sci 2009 30(6) S. 531-534

Long-term use of cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Von Wade, Makela, House, Bateman, Robson im Mult Scler 2006 12(5) S. 639-645

Treatment of human spasticity with 9-tetra-hydrocannabinol. Von Petro, Ellenberger im Clin Pharmacol 1981 (Sup. 21) S. 413-416

The effect of D9-THC on human spasticity. Von Hanigan, Destree, Truong im Clin Pharmacol Ther 1986, 39 S. 198

Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Von Conte, Bettolo, Onesti im Eur J Pain 2009 13(5) S. 472-477

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trail. Von Zajicek, Fox, Sanders im Lancet 2003; 362(9385) S. 1517-1526

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiplse sclerosis: a randomized, double-blindm placebo-controlles, crossover study. Von Vaney, Heinzel-Gutenbrunner, Jobin im Multiple Sclerosis 2004 10(4): S.417-424

The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Von Hagenbach, Luz, Ghafoor im Spinal Cord 2007 45(8) S.551-562

A randomized double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Von Pooyania, Ethans, Szturm, Casey, Perry im Arch Phys Med Rehabild 2010 91(5) S. 703-707

D9-THC in the treatment of spasticity associated with multiple sclerosis. Von Ungerleider, Andyrsiak, Fairbanks, Ellison, Myers im Adv Alcohol Substance Abuse 1987 7 S. 39-50

For the Sativex Spasticity in MS Study Group: Randomized controlled trail of cannabis-bases medicine in spasticity caused by multiple sclerosis. Von Collin, Davies, Mutiboko, Ratcliffe im Eur J Neurology 2007 14(3) S. 290-296

Appetitlosigkeit

Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trail. Von Abrams, Hilton, Leister im Ann Intern Med 2003 139(4) S. 258-266

Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Von Jatoi, Windschitl, Loprinzi im J Clin Oncol 2002; 20(2) S. 567-573

Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer´s disease. Von Volicer, Stelly, Morris, McLaughlin, Volicer im Int J Geriatr Psychiatry 1997 12 S.913-919

Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Von Haney, Rabkin, Gunderson, Foltin im Psychopharmacology (Berl) 2005 181(1): S. 170-178

Effect of dronabinol on nutritional status in HIV infection. Von Struwe, Kaempfer, Geiger im Ann Pharmacother 1993 27 S.827-831

Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Von Bedi, Foltin, Gunderson im Psychopharmacology (Berl) 2010; 212(4) S. 675-686

Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndromes: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trail from the Cannabis-In-Cachexia-Study Group. Von Cannabis-In-Cachexia-Study-Group, Strasser, Luftner im J Clin Oncol 2006 24(21) S. 3394-3400

Delta-9-tetrahydrocannabinol may palliate altered chemosnsory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trail. Von Brisbois, de Kock, Watanabe im Ann Oncol 2011 22(9) S. 2086-2093

Delta-9-tetrahydrocannabinols as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. Von Regelson, Butler, Schulz im Braude MC, Szara Pharmacology of marihuana. Vol 2. New York: Raven Press 1976 S. 763-776

The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. Von Timpone, Wright, Li im AIDS Res Hum Retroviruses 1997 13 S. 305-315

Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Von Beal, Olson, Laubenstein im J Pain Sympt Manag 1995 10(2) S. 89-97

NCCN Clinical Practice Guidelines in Oncology: Antiemesis V.3.2008 von National Comprehensive Cancer Network